Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer

Acid secretion inhibitors, such as proton pump inhibitors (PPIs) and potassium competitive acid blockers (PCABs), are used to treat ulcers after endoscopic submucosal dissection (ESD) for early gastric cancer. These drugs can influence serum gastrin and pepsinogen (PG) levels; however, their definit...

Full description

Saved in:
Bibliographic Details
Main Authors: Maidina Abuduwaili, Tomoyuki Boda, Masanori Ito, Hidehiko Takigawa, Takahiro Kotachi, Taiji Matsuo, Shiro Oka, Shinji Tanaka
Format: Article
Language:English
Published: Wiley 2022-01-01
Series:Gastroenterology Research and Practice
Online Access:http://dx.doi.org/10.1155/2022/2830227
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849407612911616000
author Maidina Abuduwaili
Tomoyuki Boda
Masanori Ito
Hidehiko Takigawa
Takahiro Kotachi
Taiji Matsuo
Shiro Oka
Shinji Tanaka
author_facet Maidina Abuduwaili
Tomoyuki Boda
Masanori Ito
Hidehiko Takigawa
Takahiro Kotachi
Taiji Matsuo
Shiro Oka
Shinji Tanaka
author_sort Maidina Abuduwaili
collection DOAJ
description Acid secretion inhibitors, such as proton pump inhibitors (PPIs) and potassium competitive acid blockers (PCABs), are used to treat ulcers after endoscopic submucosal dissection (ESD) for early gastric cancer. These drugs can influence serum gastrin and pepsinogen (PG) levels; however, their definite effects remain unclear. This open-label, randomized study investigated the effect of acid secretion inhibitors on the serum gastrin and pepsinogen levels. In total, 76 patients were enrolled in the study. They underwent gastric ESD and received a PPI (n=21) or PCAB (n=55). Changes in the serum gastrin and PG levels before and 4 weeks after administration were examined. Patient factors associated with the alteration of serum PG or gastrin levels were identified. The median serum levels of gastrin, PGI, and PGII before the administration of the acid secretion inhibitors were 110.5 pg/mL, 36.4 ng/mL, and 8.9 ng/mL, respectively; after administration, the levels increased to 300 pg/mL, 64.7 ng/mL, and 15.8 ng/mL, respectively (P<0.01). Univariate analysis revealed that PCABs led to a more significant increase in the serum gastrin and PG levels as compared to PPIs. Furthermore, the PG levels were significantly increased in patients with previous Helicobacter pylori infections than in those with current infections. In conclusion, the serum gastrin and PG levels increased after the use of acid secretion inhibitors. This elevation was affected by the type of drug used, whereas the elevation in PGs was affected by the patient’s background as well.
format Article
id doaj-art-485b96b367c44262bbb4a65a01041c7d
institution Kabale University
issn 1687-630X
language English
publishDate 2022-01-01
publisher Wiley
record_format Article
series Gastroenterology Research and Practice
spelling doaj-art-485b96b367c44262bbb4a65a01041c7d2025-08-20T03:36:01ZengWileyGastroenterology Research and Practice1687-630X2022-01-01202210.1155/2022/2830227Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric CancerMaidina Abuduwaili0Tomoyuki Boda1Masanori Ito2Hidehiko Takigawa3Takahiro Kotachi4Taiji Matsuo5Shiro Oka6Shinji Tanaka7Department of EndoscopyDepartment of EndoscopyDepartment of General Internal MedicineDepartment of EndoscopyDepartment of EndoscopyDepartment of EndoscopyDepartment of Gastroenterology and MetabolismDepartment of EndoscopyAcid secretion inhibitors, such as proton pump inhibitors (PPIs) and potassium competitive acid blockers (PCABs), are used to treat ulcers after endoscopic submucosal dissection (ESD) for early gastric cancer. These drugs can influence serum gastrin and pepsinogen (PG) levels; however, their definite effects remain unclear. This open-label, randomized study investigated the effect of acid secretion inhibitors on the serum gastrin and pepsinogen levels. In total, 76 patients were enrolled in the study. They underwent gastric ESD and received a PPI (n=21) or PCAB (n=55). Changes in the serum gastrin and PG levels before and 4 weeks after administration were examined. Patient factors associated with the alteration of serum PG or gastrin levels were identified. The median serum levels of gastrin, PGI, and PGII before the administration of the acid secretion inhibitors were 110.5 pg/mL, 36.4 ng/mL, and 8.9 ng/mL, respectively; after administration, the levels increased to 300 pg/mL, 64.7 ng/mL, and 15.8 ng/mL, respectively (P<0.01). Univariate analysis revealed that PCABs led to a more significant increase in the serum gastrin and PG levels as compared to PPIs. Furthermore, the PG levels were significantly increased in patients with previous Helicobacter pylori infections than in those with current infections. In conclusion, the serum gastrin and PG levels increased after the use of acid secretion inhibitors. This elevation was affected by the type of drug used, whereas the elevation in PGs was affected by the patient’s background as well.http://dx.doi.org/10.1155/2022/2830227
spellingShingle Maidina Abuduwaili
Tomoyuki Boda
Masanori Ito
Hidehiko Takigawa
Takahiro Kotachi
Taiji Matsuo
Shiro Oka
Shinji Tanaka
Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
Gastroenterology Research and Practice
title Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
title_full Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
title_fullStr Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
title_full_unstemmed Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
title_short Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer
title_sort serum gastrin and pepsinogen levels after administration of acid secretion inhibitors for ulcers due to endoscopic submucosal dissection in patients with early gastric cancer
url http://dx.doi.org/10.1155/2022/2830227
work_keys_str_mv AT maidinaabuduwaili serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT tomoyukiboda serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT masanoriito serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT hidehikotakigawa serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT takahirokotachi serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT taijimatsuo serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT shirooka serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer
AT shinjitanaka serumgastrinandpepsinogenlevelsafteradministrationofacidsecretioninhibitorsforulcersduetoendoscopicsubmucosaldissectioninpatientswithearlygastriccancer